Statistical Issues On Objective, Design, And Analysis Of Noninferiority Active-controlled Clinical Trial
暂无分享,去创建一个
Yi Tsong | H M James Hung | Lu Cui | Sue-Jane Wang | H. M. Hung | Y. Tsong | Lu Cui | Sue Jane Wang
[1] S S Ellenberg,et al. Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues , 2000, Annals of Internal Medicine.
[2] T. Fleming. Evaluation of active control trials in AIDS. , 1990, Journal of acquired immune deficiency syndromes.
[3] J. Mau,et al. A statistical assessment of clinical equivalence. , 1988, Statistics in medicine.
[4] L. Fisher,et al. Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. , 2001, American heart journal.
[5] J A Lewis,et al. Trials to assess equivalence: the importance of rigorous methods , 1996, BMJ.
[6] A. Ebbutt,et al. Practical issues in equivalence trials. , 1998, Statistics in medicine.
[7] S D Walter,et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. , 1997, Journal of clinical epidemiology.
[8] R. Kay. Statistical Principles for Clinical Trials , 1998, The Journal of international medical research.
[9] L. Fisher. Active control trials: what about a placebo? A method illustrated with clopidogrel, aspirin and placebo , 1998 .
[10] J Röhmel,et al. Therapeutic equivalence investigations: statistical considerations. , 1998, Statistics in medicine.
[11] William C Blackwelder. Showing a treatment is good because it is not bad: when does "noninferiority" imply effectiveness? , 2002, Controlled clinical trials.
[12] E. Holmgren,et al. Establishing equivalence by showing that a specified percentage of the effect of the active control over placebo is maintained. , 1999, Journal of biopharmaceutical statistics.
[13] B. Wiens,et al. Choosing an equivalence limit for noninferiority or equivalence studies. , 2002, Controlled clinical trials.
[14] J P Siegel,et al. Equivalence and noninferiority trials. , 2000, American heart journal.
[15] Yi Tsong,et al. Utility and pitfalls of some statistical methods in active controlled clinical trials. , 2002, Controlled clinical trials.
[16] T R Fleming,et al. Treatment evaluation in active control studies. , 1987, Cancer treatment reports.
[17] Yi Tsong,et al. Some fundamental issues with non‐inferiority testing in active controlled trials , 2002, Statistics in medicine.
[18] Donald J. Schuirmann. A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability , 1987, Journal of Pharmacokinetics and Biopharmaceutics.
[19] W C Blackwelder,et al. "Proving the null hypothesis" in clinical trials. , 1981, Controlled clinical trials.
[20] R. Temple,et al. Problems in interpreting active control equivalence trials. , 1996, Accountability in research.
[21] T R Fleming,et al. Design and interpretation of equivalence trials. , 2000, American heart journal.
[22] David F. Kong,et al. Statistical Methods for Comparison to Placebo in Active-Control Trials , 2001 .
[23] Y Tsong,et al. Group sequential test strategies for superiority and non‐inferiority hypotheses in active controlled clinical trials , 2001, Statistics in medicine.
[24] R. Simon,et al. Planning and monitoring of equivalence studies. , 1988, Biometrics.
[25] Walter W. Hauck,et al. Some Issues in the Design and Analysis of Equivalence Trials , 1999 .